QLT Unit Pays $112.5M To Resolve Drug Dispute
A U.S. unit of Canada's generic drug maker QLT Inc. has agreed to shell out $112.5 million to settle a patent infringement lawsuit over its prostate cancer drug Eligard....To view the full article, register now.
Already a subscriber? Click here to view full article